ATE421505T1 - 4-aminobenzofuranverbindungen als phosphodiesterase-4-inhibitoren - Google Patents

4-aminobenzofuranverbindungen als phosphodiesterase-4-inhibitoren

Info

Publication number
ATE421505T1
ATE421505T1 AT03765684T AT03765684T ATE421505T1 AT E421505 T1 ATE421505 T1 AT E421505T1 AT 03765684 T AT03765684 T AT 03765684T AT 03765684 T AT03765684 T AT 03765684T AT E421505 T1 ATE421505 T1 AT E421505T1
Authority
AT
Austria
Prior art keywords
phosphodiesterase
inhibitors
compounds
aminobenzofuran
aminobenzofuran compounds
Prior art date
Application number
AT03765684T
Other languages
English (en)
Inventor
Richard Schumacher
Allan Hopper
Ashok Tehim
Original Assignee
Memory Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharmaceutical Corp filed Critical Memory Pharmaceutical Corp
Application granted granted Critical
Publication of ATE421505T1 publication Critical patent/ATE421505T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
AT03765684T 2002-07-19 2003-07-18 4-aminobenzofuranverbindungen als phosphodiesterase-4-inhibitoren ATE421505T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39672602P 2002-07-19 2002-07-19

Publications (1)

Publication Number Publication Date
ATE421505T1 true ATE421505T1 (de) 2009-02-15

Family

ID=30770939

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03765684T ATE421505T1 (de) 2002-07-19 2003-07-18 4-aminobenzofuranverbindungen als phosphodiesterase-4-inhibitoren

Country Status (20)

Country Link
US (2) US7655802B2 (de)
EP (1) EP1549619B1 (de)
JP (1) JP2006502995A (de)
CN (2) CN100381425C (de)
AT (1) ATE421505T1 (de)
AU (2) AU2003256601B2 (de)
BR (1) BR0313000A (de)
CA (1) CA2492911A1 (de)
CO (1) CO5680420A2 (de)
DE (1) DE60325984D1 (de)
ES (1) ES2323688T3 (de)
HK (1) HK1081194A1 (de)
HR (1) HRP20050082A2 (de)
IL (1) IL166164A0 (de)
MX (1) MXPA05000825A (de)
NO (1) NO20050871L (de)
NZ (1) NZ537725A (de)
RU (1) RU2354648C2 (de)
WO (1) WO2004009557A1 (de)
ZA (1) ZA200500436B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
EP1893203A2 (de) * 2005-05-31 2008-03-05 Boehringer Ingelheim International GmbH Arzneimittel mit einem betamimetikum in verbindung mit einem anticholinergikum und einem pde-iv-hemmer
RU2442777C2 (ru) 2006-01-31 2012-02-20 Эррэй Биофарма Инк. Ингибиторы киназ и способы их применения
JP5517935B2 (ja) 2007-08-17 2014-06-11 エルジー・ライフ・サイエンシーズ・リミテッド 細胞壊死阻害剤としてのインドール及びインダゾール化合物
US8314789B2 (en) * 2007-09-26 2012-11-20 Autodesk, Inc. Navigation system for a 3D virtual scene
MX2010005838A (es) * 2007-11-30 2010-09-14 Yu Fen Chi Medicina antimelancolica preparada con materiales de camp de azufaifa.
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
ES2649144T3 (es) 2012-11-08 2018-01-10 Pfizer Inc. Compuestos heteroaromáticos y su uso como ligandos de dopamina D1
WO2015166370A1 (en) * 2014-04-28 2015-11-05 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE580519C (de) * 1932-02-26 1933-07-12 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von 2-Oxy-3-arylaminonaphthalinen
US3259623A (en) 1963-06-14 1966-07-05 Olin Mathieson Process for preparing 2-(secondary amino)-halogenopyrimidines
GB1337389A (en) 1969-12-10 1973-11-14 Ici Ltd Pyrimidine derivatives
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
FR2244520B1 (de) 1973-07-06 1977-02-04 Ugine Kuhlmann
US4524373A (en) 1982-02-24 1985-06-18 Kanzaki Paper Manufacturing Co., Ltd. Fluoran derivatives as new compounds, process for preparing the same and recording system utilizing the same as colorless chromogenic material
GB2202434B (en) * 1987-03-25 1990-03-28 Tachi S Co Apparatus for manufacturing a seat
US5221682A (en) * 1989-06-28 1993-06-22 Hoechst-Roussel Pharmaceuticals Incorporated Heteroarylamino- and heteroaryloxypyridinamines and related compounds
US5935978A (en) * 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US5698711A (en) * 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
GB9311281D0 (en) * 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
US5204226A (en) 1991-03-04 1993-04-20 International Business Machines Corporation Photosensitizers for polysilanes
US5204366A (en) 1991-06-10 1993-04-20 American Cyanamid Company 2,5-dioxo-3-pyrroline-1-acetanilide fungicidal agents, compositions and method for use thereof
US6096768A (en) * 1992-01-28 2000-08-01 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
AU670949B2 (en) 1992-06-15 1996-08-08 Celltech Limited Trisubstituted phenyl derivatives as selective phosphodiesterase IV inhibitors
US5679696A (en) * 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
EP0652868B1 (de) 1992-07-28 2004-11-10 Aventis Pharma Limited Inhibitoren von c-amp phosphodiesterase
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
TW263495B (de) 1992-12-23 1995-11-21 Celltech Ltd
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
JPH09501405A (ja) 1993-05-27 1997-02-10 スミスクライン・ビーチャム・ラボラトワール・ファルマソーティク 抗不整脈用ｎ−置換３−ベンズアゼピンまたはイソキノリン
CN1046939C (zh) * 1993-07-02 1999-12-01 比克·古尔顿·劳姆贝尔格化学公司 氟烷氧基取代的苯甲酰胺类及其制备方法和应用
GB9315595D0 (en) 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
JPH07206789A (ja) 1993-09-01 1995-08-08 Taisho Pharmaceut Co Ltd コンブレタスタチン類縁化合物
CA2174080A1 (en) 1993-10-12 1995-04-20 Paul Edward Aldrich 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
GB9326600D0 (en) * 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
DE69433594T2 (de) * 1993-12-22 2004-08-05 Celltech R&D Ltd., Slough Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
US6245774B1 (en) * 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412571D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
FR2729142A1 (fr) 1995-01-06 1996-07-12 Smithkline Beecham Lab Nouvelles amines heterocycliques, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu'agents anti-arythmiques
US5731477A (en) 1995-01-31 1998-03-24 Smithkline Beecham Corporation Method for synthesis of aryl difluoromethyl ethers
IT1275433B (it) 1995-05-19 1997-08-07 Smithkline Beecham Farma Derivati di diarildiammine
WO1996036611A1 (en) * 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
FR2735777B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9603723D0 (en) * 1996-02-22 1996-04-24 Merck & Co Inc Diphenyl pyridyl derivatives as pde iv inhibitors
US5710170A (en) * 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
TR199802685T2 (xx) * 1996-06-25 1999-03-22 Pfizer Inc �kameli/katk�l� indazol t�revleri
IL128642A0 (en) * 1996-09-04 2000-01-31 Pfizer Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
CA2295106C (en) 1997-06-24 2007-03-13 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivatives
US5919937A (en) * 1997-10-29 1999-07-06 Merck & Co., Inc. Process for phosphodiesterase IV inhibitors
CA2299399C (en) * 1997-11-25 2004-04-06 Warner-Lambert Company Benzenesulfonamide inhibitors of pde-iv and their therapeutic use
DK1049676T3 (da) 1997-12-24 2006-01-16 Ortho Mcneil Pharm Inc 4-[Aryl(piperidin-4-yl)]aminobenzamider, som binder til delta-opioidreceptoren
JP3542482B2 (ja) 1997-12-25 2004-07-14 日研化学株式会社 ３−アニリノ−２−シクロアルケノン誘導体
PT1117659E (pt) * 1998-09-29 2004-04-30 Wyeth Corp Cianoquinolinas substituidas como inibidores de tirosina-quinases de proteinas
AU764005B2 (en) * 1999-02-25 2003-08-07 Merck Frosst Canada & Co. PDE IV inhibiting compounds, compositions and methods of treatment
US6180650B1 (en) * 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6200993B1 (en) * 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
GB2350110A (en) * 1999-05-17 2000-11-22 Bayer Ag Pharmaceutically active benzofurans
TR200103352T2 (tr) 1999-05-21 2005-03-21 Bristol-Myers Squibb Company Kinas pirolotriazin inhibitörleri
JP4434362B2 (ja) * 1999-06-28 2010-03-17 興和創薬株式会社 ホスホジエステラーゼ阻害剤
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
WO2001025220A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
EP1235804A1 (de) * 1999-11-27 2002-09-04 Dong Wha Pharmaceutical Industrial Co. Ltd. Neue 3-nitropyridin-derivate und diese derivate enthaltende pharmazeutische gemische
ES2254077T3 (es) 1999-12-18 2006-06-16 Wella Aktiengesellschaft Derivados 2-aminoalquil-1,4-diaminobenceno y su utilizacion para el teñido de fibras.
MY123585A (en) 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
US7105530B2 (en) * 2000-12-21 2006-09-12 Smithkline Beecham Corporation Pyrimidineamines as angiogenesis modulators
US6699890B2 (en) * 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
WO2002074726A2 (en) 2001-01-22 2002-09-26 Memory Pharmaceuticals Corporation Aniline derivatives useful as phosphodiesterase 4 inhibitors
US20030130264A1 (en) 2001-02-16 2003-07-10 Tularik Inc. Methods of using pyrimidine-based antiviral agents
US20030149052A1 (en) 2002-01-22 2003-08-07 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
AU2003256616B2 (en) 2002-07-19 2009-08-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
JP2006508987A (ja) 2002-11-19 2006-03-16 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ４阻害剤
MY141255A (en) 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs

Also Published As

Publication number Publication date
AU2003256601A1 (en) 2004-02-09
NZ537725A (en) 2006-08-31
MXPA05000825A (es) 2005-08-29
CN100381425C (zh) 2008-04-16
US20070123570A1 (en) 2007-05-31
CN101423497A (zh) 2009-05-06
WO2004009557A1 (en) 2004-01-29
DE60325984D1 (de) 2009-03-12
HK1081194A1 (en) 2006-05-12
US7655802B2 (en) 2010-02-02
US20100093806A1 (en) 2010-04-15
RU2005104820A (ru) 2005-10-10
RU2354648C2 (ru) 2009-05-10
ES2323688T3 (es) 2009-07-23
AU2010200233A1 (en) 2010-02-11
EP1549619A1 (de) 2005-07-06
BR0313000A (pt) 2005-07-12
AU2003256601B2 (en) 2009-10-29
CO5680420A2 (es) 2006-09-29
ZA200500436B (en) 2006-07-26
CN1668602A (zh) 2005-09-14
IL166164A0 (en) 2006-01-15
CA2492911A1 (en) 2004-01-29
EP1549619B1 (de) 2009-01-21
HRP20050082A2 (en) 2005-06-30
JP2006502995A (ja) 2006-01-26
NO20050871L (no) 2005-02-18

Similar Documents

Publication Publication Date Title
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
NO20050871L (no) 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer
NO20052976D0 (no) Fosfodiesterase-4-inhibitorer.
DE60313472D1 (de) Pyrrolidindion-substituierte piperidin-phthalazone als pde4-inhibitoren
ATE348616T1 (de) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
ATE506354T1 (de) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
EA200601007A1 (ru) 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
EA200700188A1 (ru) Производные замещенного 2-алкилхиназолинона как ингибиторы parp
EA200700185A1 (ru) Производные хиназолиндиона в качестве ингибиторов parp
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
DK1501507T3 (da) Tetrahydropyranyl-cyclopentyl-tertrahydropyridopyrindin-modulatorer af kemokin-receptor-aktivitet
NO20062950L (no) 5,7-diaminopyrazolo `43-Dlpyrimidiner med PDE-5 inhiberende aktivitet
EA200701779A1 (ru) Производные (1,5-дифенил-1н-пиразол-3-ил)оксадиазола, их получение и их применение в терапии
ATE444065T1 (de) 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-deriva e als pde-4-hemmer zur behandlung von neurologischen syndromen
BR0313969A (pt) Inibidores de oxitocina
ATE368040T1 (de) Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase- inhibitoren
ATE399168T1 (de) Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren
DE60314381D1 (de) Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
DE60041001D1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
ATE399169T1 (de) Imidazopyridinderivate als inhibitoren der induzierbaren no-synthase
ATE372982T1 (de) 2-(3-sulfonylamino-2-oxopyrrolidin-1- yl)propanamide als factor xa inhibitoren
ATE398617T1 (de) Imidazoä4,5-büpyridinderivate als inhibitoren der induzierbaren no-synthase

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1549619

Country of ref document: EP

REN Ceased due to non-payment of the annual fee